Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
2.
Clin Exp Immunol ; 167(1): 120-8, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22132891

RESUMO

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) is a rare syndrome due to a mutation in the forkhead box protein 3 gene (FOXP3) leading to an impaired regulatory T cell (T(reg) ) activity associated both with skewed T helper type 2 (Th2) response and autoreactive phenomena. The purpose of this study was to describe a combined proteomics and genomics approach to comprehensively evaluate clinical and immunological phenotypes of patients affected by IPEX. T cell receptor (TCR)-Vß repertoire and peripheral blood lymphocytes phenotype from three brothers affected by IPEX were studied by flow cytometry. Specific immunoglobulin (Ig)E were evaluated by means of an allergenic molecules microarray [immuno solid-phase allergen chip (ISAC)]. Total RNA was extracted and hybridized to Affymetrix oligonucleotide arrays to obtain quantitative gene-expression levels. No FOXP3 protein was detectable within CD127(-) CD25(high) CD4(+) T cells from peripheral blood. A T cell-naive phenotype (CD62L(+) CD45R0(-)) associated with a reduction of both CD26 and CD7 expression and a TCR-Vß 8 and 22 family expansions were found. B lymphocytes were mainly CD5(+) (B1) cells expressing a naive phenotype (tcl1(+) CD27(-)). The three IPEX patients had severe food allergy and specific IgE reactivity to cow's milk allergens, a hen's egg allergen and a wheat allergen. Gene expression profile analysis revealed a dysregulation associated mainly with Th1/Th2 pathways. The multiplexing evaluation reported in this study represents a comprehensive approach in the assessment of genetic conditions affecting the immune system such as the IPEX syndrome, paving the way for the development of diagnostic tools to improve the standard clinical and immunological profiling of the disease.


Assuntos
Doenças do Sistema Endócrino/genética , Hipersensibilidade Alimentar/genética , Fatores de Transcrição Forkhead/deficiência , Genes Ligados ao Cromossomo X , Doenças Genéticas Ligadas ao Cromossomo X/genética , Genômica/métodos , Síndromes de Imunodeficiência/genética , Proteômica/métodos , Adolescente , Adulto , Doenças do Sistema Endócrino/sangue , Doenças do Sistema Endócrino/imunologia , Hipersensibilidade Alimentar/sangue , Hipersensibilidade Alimentar/imunologia , Fatores de Transcrição Forkhead/genética , Perfilação da Expressão Gênica , Doenças Genéticas Ligadas ao Cromossomo X/sangue , Doenças Genéticas Ligadas ao Cromossomo X/imunologia , Humanos , Imunoglobulina E/imunologia , Síndromes de Imunodeficiência/sangue , Imunofenotipagem , Linfoma Difuso de Grandes Células B/genética , Linfoma Difuso de Grandes Células B/patologia , Masculino , Análise de Sequência com Séries de Oligonucleotídeos , Receptores de Antígenos de Linfócitos T alfa-beta/genética , Análise de Sequência de DNA , Subpopulações de Linfócitos T/imunologia , Neoplasias Tonsilares/genética , Neoplasias Tonsilares/patologia , Adulto Jovem
3.
Cell Death Dis ; 2: e151, 2011 Apr 28.
Artigo em Inglês | MEDLINE | ID: mdl-21525938

RESUMO

Sézary syndrome (SS) is an incurable leukemic variant of cutaneous T-cell lymphoma and its pathogenesis is still unknown. Diagnosis/prognosis may strongly ameliorate the management of SS individuals. Here, we profiled the expression of 470 microRNAs (miRNAs) in a cohort of 22 SS patients, and we identified 45 miRNAs differentially expressed between SS and controls. Using predictive analysis, a list of 19 miRNAs, including miR-21, miR-214, miR-486, miR-18a, miR-342, miR-31 and let-7 members were also found. Moreover, we defined a signature of 14 miRNAs including again miR-21, potentially able to discriminate patients with unfavorable and favorable outcome. We validated our data for miR-21, miR-214 and miR-486 by qRT-PCR, including an additional set of array-independent SS cases. In addition, we also provide an in vitro evidence for a contribution of miR-214, miR-486 and miR-21 to apoptotic resistance of CTCL cell line.


Assuntos
Biomarcadores Tumorais/genética , Sobrevivência Celular/genética , Perfilação da Expressão Gênica , MicroRNAs/genética , Síndrome de Sézary/genética , Neoplasias Cutâneas/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Apoptose/genética , Biomarcadores Tumorais/metabolismo , Linhagem Celular Tumoral , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , MicroRNAs/metabolismo , Pessoa de Meia-Idade , Nucleossomos/metabolismo , Síndrome de Sézary/metabolismo , Síndrome de Sézary/mortalidade , Neoplasias Cutâneas/metabolismo , Neoplasias Cutâneas/mortalidade , Linfócitos T/metabolismo , Regulação para Cima
4.
Ultrasound Obstet Gynecol ; 30(3): 312-7, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17688308

RESUMO

OBJECTIVES: To calculate the risk of developing pre-eclampsia (PET) in a consecutive series of low-risk women at 18-24 weeks' gestation, using recently published logistic regression models. METHODS: This was a prospective study, with complete follow-up, in a consecutive series of unselected low-risk singleton pregnancies. Uterine artery pulsatility index as well as a combination of maternal factors were recorded at 18-24 weeks' gestation. The distribution of the estimated risks for the 16 PET patients was compared with that obtained for 136 women who had a normal pregnancy, as assessed by routine testing. A receiver-operating characteristics (ROC) curve was plotted to evaluate the detection rate at fixed false-positive rates (FPRs) of 5%, 10% and 20% and the corresponding odds cut-offs. RESULTS: Just 1/16 (6.2%) women with PET developed the disease before the 34(th) week of gestation. Using the 'All PET' logistic regression model, for 16 PET cases the overall median odds was 1 : 1454, higher compared with that of 1 : 41635 estimated for controls. Using the 'PET >or= 34 weeks' model, the median odds of the 15 women who developed PET late was 1 : 3405, compared with 1 : 40785 for controls. In the case of PET before 34 weeks, the risk was 1 : 426373 vs. 1 : 4159823126 estimated for controls ('PET < 34 weeks' model). Detection rates for the All PET model were 18%, 50% and 62% at a FPR of 5%, 10% and 20%, respectively. For the PET >or= 34 weeks model these detection rates were 6%, 46% and 60%, respectively. CONCLUSION: Even though the individual odds estimation is too low to represent the real risk of PET, the recently published logistic regression models detected more than 60% of PET at a FPR of 20% for both All PET and PET >or= 34 weeks models. Using these models in clinical practice does not seem to give any significant improvement over Doppler alone in the prediction of PET, but the use of a PET-specific odds instead of an actual Doppler value alone seems to be useful for clinical management.


Assuntos
Pré-Eclâmpsia/diagnóstico por imagem , Adulto , Antropometria , Artérias/diagnóstico por imagem , Artérias/fisiopatologia , Métodos Epidemiológicos , Reações Falso-Positivas , Feminino , Humanos , Pessoa de Meia-Idade , Pré-Eclâmpsia/fisiopatologia , Gravidez , Fluxo Pulsátil , Ultrassonografia Pré-Natal/métodos , Útero/irrigação sanguínea
5.
J Thromb Haemost ; 4(4): 848-60, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16634756

RESUMO

BACKGROUND: Megakaryopoiesis represents a multi-step, often unclear, process leading to commitment, differentiation, and maturation of megakaryocytes (MKs) that release platelets. AIM: To identify the novel genes that might help to clarify the molecular mechanisms of megakaryocytopoiesis and be regarded as potential candidates of inherited platelet defects, global gene expression of hematopoietic lineages was carried out. METHODS: Human cord blood was used to purify CD34+ stem cells and in vitro expand CD41+ cells and burst-forming unit-erythroid (BFU-E). We investigated the expression profiles of these three hematopoietic lineages in the Affymetrix system and selected genes specifically expressed in MKs by comparing transcripts of the different lineages using the dchip and pam algorithms. RESULTS: A detailed characterization of MK population showed that 99% of cells expressed the CD41 antigen whereas 73% were recognizable as terminally differentiated fetal MKs. The profile of these cells was compared with that of CD34+ cells and BFU-E allowing us to select 70 transcripts (MK-core), which represent not only the genes with a well-known function in MKs, but also novel genes never detected or characterized in these cells. Moreover, the specific expression was confirmed at both RNA and protein levels, thus validating the 'MK-core' isolated by informatics tools. CONCLUSIONS: This is a global gene expression that for the first time depicts a well-characterized population of cord blood-derived fetal MKs. Novel genes have been detected, such as those encoding components of the extracellular matrix and basal membrane, which have been found in the cytoplasm of Mks, suggesting that new physiological aspects of MKs should be studied.


Assuntos
Sangue Fetal/citologia , Glicoproteína IIb da Membrana de Plaquetas/biossíntese , Trombopoese/fisiologia , Anticorpos Monoclonais/metabolismo , Antígenos CD34/biossíntese , Antígenos CD34/metabolismo , Células Precursoras Eritroides/metabolismo , Citometria de Fluxo , Humanos , Técnicas In Vitro , Microscopia de Fluorescência , Família Multigênica , Análise de Sequência com Séries de Oligonucleotídeos , Glicoproteína IIb da Membrana de Plaquetas/química , RNA/química , RNA/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa
6.
J Dent Res ; 82(7): 551-7, 2003 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12821718

RESUMO

Odontogenic tumors are rare neoplasms arising from the odontogenic apparatus. We aimed to identify molecular characteristics associated with odontogenic tumorigenesis and malignancy. To this end, we investigated the expression level of human genes by using, for the first time in odontogenic tumors, the technique of expression profiling. Gene expression alterations common to all six odontogenic tumors were identified by the use of cDNA microarrays containing 19,000 human cDNAs. Statistical analysis on a subset of 4974 cDNAs present in the biopsies identified 506 distinct genes associated with the tumors (p-value < 0.01). Gene ontology analysis of the cellular processes which were differentially regulated in odontogenic tumors was accomplished by the use of a subset of 1409 annotated genes. Finally, 43 cDNAs differentiated the three malignant odontogenic tumors (ameloblastic carcinoma, clear cell odontogenic tumor, granular cell odontogenic tumor) from the three benign ameloblastoma biopsies (p < 0.01). The identified genes might help us better classify borderline odontogenic tumors.


Assuntos
Neoplasias Maxilomandibulares/genética , Tumores Odontogênicos/genética , Ameloblastoma/genética , Ameloblastoma/patologia , Perfilação da Expressão Gênica , Regulação Neoplásica da Expressão Gênica , Humanos , Neoplasias Maxilomandibulares/classificação , Neoplasias Maxilomandibulares/patologia , Tumores Odontogênicos/classificação , Tumores Odontogênicos/patologia , Análise de Sequência com Séries de Oligonucleotídeos , Análise de Componente Principal
7.
Neurosci Lett ; 184(2): 97-100, 1995 Jan 23.
Artigo em Inglês | MEDLINE | ID: mdl-7724055

RESUMO

The ability of adenosine agonists to modulate the electrically evoked release of acetylcholine (ACh) from [3H]choline preloaded guinea-pig superior cervical ganglia (SCG) was investigated. The adenosine A1-receptor selective agonist N6-cyclohexyladenosine (CHA) and 2-chloroadenosine (2-CADO) inhibited the evoked transmitter release, the effect being reversed by the A1-receptor selective antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), and by sulmazole (SUL), which blocks both the A1-receptor and the adenylate cyclase inhibitory regulator Gi. In whole ganglia, CHA decreased both the basal and the forskolin (FSK)-stimulated cyclic AMP synthesis. The latter effect was again prevented by the A1 antagonist DPCPX. These results are compatible with the existence, in the guinea-pig SCG, of adenosine A1-receptors, part of which are located on the presynaptic nerve terminals mediating an inhibition of ACh release.


Assuntos
Acetilcolina/metabolismo , Adenosina/farmacologia , AMP Cíclico/biossíntese , Gânglio Cervical Superior/metabolismo , Adenosina/análogos & derivados , Animais , Colforsina/farmacologia , Depressão Química , Estimulação Elétrica , Cobaias , Imidazóis/farmacologia , Inibidores de Fosfodiesterase/farmacologia , Terminações Pré-Sinápticas/efeitos dos fármacos , Terminações Pré-Sinápticas/metabolismo , Agonistas do Receptor Purinérgico P1 , Antagonistas de Receptores Purinérgicos P1 , Gânglio Cervical Superior/efeitos dos fármacos , Sistema Nervoso Simpático/fisiologia , Xantinas/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA